Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Castellon
Clinical trial register · Spain

Clinical Trials in Castellon, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5875 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC
5875
Studies in scope
all four open statuses
3096
Recruiting now
open to new participants
1137
Lead sponsors
across recruiting studies
Top sites
Barcelona 3238 Madrid 3046 Valencia 1215 Seville 1054 Málaga 746
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Universitat Jaume I8 AstraZeneca8 Janssen Research & Development, LLC5 MedSIR3 Takeda2
Site location
Barcelona3238 Madrid3046 Valencia1215 Seville1054 Málaga746
All 453 locations
Target enrolment
to

Trials with a site in Castellon

68 of 5875 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Spain
Start
Not yet open
Universitat Jaume I
Not applicable
40
Castellon
2026-10
Recruiting
AstraZeneca
Phase 3
1,072
Barcelona, Castellon, Granada, Las Palmas de Gran Canaria, Madrid, Valencia, Vigo
2026-08-31
Recruiting
Eikon Therapeutics
Phase 2/3
750
Jerez de la Frontera, Castellon, Barcelona, Girona, Málaga
2026-06-15
Not yet open
Cost-effectiveness and Implementation of a Transdiagnostic Internet-based Intervention for Emotional Disorders in Community Care.
NCT07345117Emotional Disorders, Depression Anxiety Disorder, Depression Disorders, Anxiety Disorders
Universitat Jaume I
Not applicable
200
Castellon
2026-04-01
Recruiting
Active Breaks and Executive Function in Scholars
NCT07538453Creativity, Executive Function (Cognition), Psychological Wellbeing
Universitat Jaume I
Not applicable
114
Castellon
2026-03-26
Active, closed
Epidemiology of Narcolepsy Type 1 and Type 2 in Spain
NCT07299097Narcolepsy Type 1, Narcolepsy Type 2
Takeda
Observational
402
Castellon, Pamplona, Alzira, Barcelona, Granada, Madrid, Seville, Vitoria-Gasteiz
2025-12-02
Recruiting
Universitat Jaume I
Not applicable
141
Castellon
2025-11-10
Recruiting
Eli Lilly and Company
Phase 3
1,630
Barcelona, Castellon, Granada, Madrid, Málaga, San Sebastián de los Reyes, Santiago de Compostela, Toledo
2025-10-22
Recruiting
Janssen Research & Development, LLC
Phase 3
220
A Coruña, Barcelona, Cadiz, Castellon, Ferrol, Jerez de la Frontera, Madrid, Málaga
2025-09-10
Recruiting
Relay Therapeutics, Inc.
Phase 3
540
Badajoz, Badalona, Barcelona, Castellon, Cáceres, El Palmar, Girona, Huelva
2025-08-26
Recruiting
Universitat Jaume I
Not applicable
20
Castellon
2025-05-01
Recruiting
Analyzing the Benefits of Using SYMPTOMS-JIT for in Vivo Exposure in Anxiety Disorders
NCT06788119Anxiety Disorders, Specific Phobia, Panic Disorder, Agoraphobia
Universitat Jaume I
Not applicable
158
Castellon
2025-04-30
Recruiting
AstraZeneca
Phase 3
830
Badajoz, Badalona, Barcelona, Castellon, Granada, Jaén, Lugo, Madrid
2025-04-10
Recruiting
BioNTech SE
Phase 3
621
Badajoz, Barcelona, Castellon, León, Madrid, Málaga, Seville, Torrejón de Ardoz
2025-02-03
Recruiting
Probelte Pharma S.L.U.
Observational
27
Barcelona, Castellon, Ciudad Real, Córdoba, Girona, Lleida, Madrid, Orihuela
2025-02-01
Not yet open
Transcranial Magnetic Stimulation in Patients with Dual Disorders
NCT06765824Major Depression, Tobacco Addiction
Cardenal Herrera University
Phase 3
36
Castellon
2025-02
Recruiting
BioNTech SE
Phase 2/3
1,580
A Coruña, Badajoz, Badalona, Barcelona, Castellon, Las Palmas de Gran Canaria, León, Lleida
2025-01-07
Recruiting
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
NCT06382948Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, ESR1 Gene Mutation
DrugsElacestrant·Everolimus
MedSIR
Phase 3
300
Barcelona, A Coruña, Alicante, Badalona, Bilbao, Burgos, Castellon, Cáceres
2024-12-05
Recruiting
AstraZeneca
Phase 3
1,160
Barcelona, Castellon, Las Palmas de Gran Canaria, Madrid, Majadahonda, Seville
2024-11-27
Recruiting
Universitat Jaume I
Not applicable
144
Castellon
2024-11-23
Recruiting
UCB Biopharma SRL
Phase 3
450
A Coruña, Badajoz, Barcelona, Castellon, Madrid, Málaga, Mérida, Sabadell
2024-11-21
Active, closed
MoonLake Immunotherapeutics AG
Phase 3
600
A Coruña, Alcobendas, Bilbao, Castellon, Madrid, Málaga, Sabadell, Santiago de Compostela
2024-10-15
Recruiting
RESTI Registry: Spanish Registry of Primary Immune Thrombocytopenia and Other Immune Thrombocytopenia
NCT06919341ITP - Immune Thrombocytopenia, Primary Immune Thrombocytopenia (ITP)
Fundación Española de Hematología y Hemoterapía
Observational
1,000
A Coruña, Palma, Barcelona, Terrassa, Bilbao, Torrelavega, Castellon, Algeciras
2024-09-27
Active, closed
MedSIR
Phase 2
165
Seville, Alicante, Barcelona, Bilbao, Castellon, Córdoba, Granada, León
2024-07-22
Recruiting
Left Septal or Deep Septal Pacing to Prevent Pacing-induced Cardiomyopathy
NCT06474819Complete Heart Block, Second Degree Atrioventricular Block Möbitz Type II
Institut d'Investigació Biomèdica de Bellvitge
Not applicable
326
Barcelona, Castellon, Granada, L'Hospitalet de Llobregat, Valencia, Zaragoza
2024-07-12
Active, closed
AstraZeneca
Phase 3
339
Barcelona, Castellon, Granada, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Majadahonda, Salamanca
2024-06-29
Active, closed
GlaxoSmithKline
Phase 4
303
Barcelona, Castellon, Córdoba, Murcia, Valladolid, VigoPontevedra, Villajoyosa
2024-06-06
Recruiting
Janssen Research & Development, LLC
Phase 3
641
A Coruña, Alzira, Barcelona, Cadiz, Castellon, Jerez de la Frontera, Madrid, Málaga
2024-04-18
Active, closed
MedSIR
Phase 2
976
A Coruña, Alicante, Barcelona, Bilbao, Castellon, Córdoba, Elche, Girona
2024-04-01
Recruiting
Fundación para la Investigación del Hospital Clínico de Valencia
Observational
70
Alicante, Badajoz, Barcelona, Candelaria, Castellon, Málaga, Murcia, Palma de Mallorca
2024-03-21
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
762
Palma, A Coruña, Barcelona, Alicante, Badalona, Castellon, Madrid, Málaga
2024-02-21
Recruiting
Universitat Jaume I
Not applicable
120
Castellon
2024-01-02
Recruiting
Institut d'Investigació Biomèdica de Bellvitge
Not applicable
90
Sant Joan d'Alacant, Castellon, Vigo, Barcelona, Girona, Santa Cruz de Tenerife, Valencia, Zaragoza
2023-11-22
Active, closed
AstraZeneca
Phase 3
5,511
A Coruña, Albacete, Alicante, Badalona, Barakaldo, Barcelona, Burgos, Castellon
2023-10-05
Recruiting
Karolinska Institutet
Not applicable
60
Castellon
2023-09-18
Active, closed
Regeneron Pharmaceuticals
Phase 2
51
Badalona, Manresa, Castellon, Madrid, Málaga, Pamplona, Valencia
2023-04-21
Recruiting
Takeda
Phase 2/3
500
Vitoria-Gasteiz, Castellon, Alzira, Barcelona, Madrid
2023-04-05
Active, closed
Janssen Research & Development, LLC
Phase 3
1,135
A Coruña, Algeciras, Barcelona, Cadiz, Castellon, L'Hospitalet de Llobregat, Lugo, Madrid
2023-03-23
Recruiting
Hemoperfusion in Critical Patients With Septic Multiorgan Dysfunction Syndrome.
NCT05044403Hemoperfusion, Multiorgan Failure, Sepsis
Hospital Clinic of Barcelona
Not applicable
48
Castellon
2023-03-01
Active, closed
Fundación EPIC
Not applicable
609
L'Hospitalet de Llobregat, A Coruña, Albacete, Alicante, Badalona, Barcelona, Cadiz, Castellon
2023-01-30
Recruiting
Gilead Sciences
Phase 3
1,514
A Coruña, Badalona, Barakaldo, Barcelona, Castellon, Cáceres, Córdoba, Donostia / San Sebastian
2022-12-12
Recruiting
Regeneron Pharmaceuticals
Observational
500
Málaga, Sabadell, Jerez de la Frontera, Castellon, Ferrol, Vigo, Almería, Jaén
2022-10-26
Active, closed
AstraZeneca
Phase 3
594
A Coruña, Barcelona, Castellon, Córdoba, Hospitalet deLlobregat, Madrid, Málaga, Ourense
2022-09-15
Active, closed
Biogen
Phase 2/3
450
Badalona, Valladolid, Castellon, Alcorcón, Majadahonda, A Coruña, Barcelona, Córdoba
2022-09-13
Active, closed
Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib
NCT05252988Early-stage Breast Cancer, HER2 Positive Breast Cancer, Hormone Receptor Positive
DrugsColesevelam·Loperamide·Neratinib
Spanish Breast Cancer Research Group
Phase 2
177
Elche, Málaga, Zaragoza, L'Hospitalet de Llobregat, Manresa, Mataró, Castellon, Valladolid
2022-08-31
By invitation
Biogen
Phase 3
864
Castellon, Santander, Seville, Barcelona
2022-06-10
Recruiting
Hospital Universitario de Fuenlabrada
Phase 4
216
Elche, Almería, Badajoz, Sant Joan Despí, Castellon, Ciudad Real, Córdoba, San Sebastián
2022-03-02
Active, closed
AstraZeneca
Phase 3
791
Bilbao (Vizcaya), Castellon, Córdoba, El Palmar, Palma de Mallorca, Sabadell (Barcelona)
2022-02-18
Recruiting
National GMA Post-market Clinical Follow-up Study (GRACE)
NCT05636709Crohn Disease, Ulcerative Colitis
Adacyte Therapeutics SL
Observational
350
Albacete, Alicante, Badalona, Barcelona, Galdakao, Castellon, Cadiz, Córdoba
2022-01-11
Active, closed
Fundación GECP
Phase 2
71
Badalona, Barcelona, L'Hospitalet de Llobregat, Castellon, Las Palmas de Gran Canaria, Jaén, A Coruña, León
2021-11-18
Active, closed
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
496
Castellon, Barcelona, Córdoba, Girona, Madrid, Málaga, Seville, Valencia
2021-03-18
Active, closed
Bayer
Phase 4
654
Santiago de Compostela, Palma de Mallorca, Badalona, Castellon, Majadahonda, Oviedo, A Coruña, Barcelona
2020-11-09
Active, closed
Spanish Breast Cancer Research Group
Phase 2
200
Santiago de Compostela, L'Hospitalet de Llobregat, Santander, Castellon, San Sebastián, Vigo, A Coruña, Alicante
2020-10-02
Active, closed
Janssen Research & Development, LLC
Phase 3
696
A Coruña, Barcelona, Castellon, Girona, Jerez de la Frontera, Madrid, Málaga, Sabadell
2020-09-23
Active, closed
Amgen
Phase 3
145
Granada, Seville, Salamanca, Barcelona, Ourense, Fuenlabrada, Castellon, Madrid
2020-02-26
Active, closed
Janssen Research & Development, LLC
Phase 3
2,517
A Coruña, Barcelona, Cadiz, Castellon, Jerez de la Frontera, Madrid, Manacor, Málaga
2019-06-11
Recruiting
Medical University of Graz
Observational
266
Castellon
2019-05-02
Active, closed
Concordance Between FFR and iFR for the Assessment of Intermediate Lesions in the Left Main Coronary Artery. A Prospective Validation of a Default Value for iFR
NCT03767621Coronary Artery Disease, Left Main Coronary Artery Stenosis, Left Main Coronary Artery Disease, Restenosis, Coronary
Fundación EPIC
Observational
300
Terrassa, Cartagena, El Palmar, Castellon, Galdakao, Albacete, Badajoz, Badalona
2019-02-19
Active, closed
Memorial Sloan Kettering Cancer Center
Phase 3
732
Oviedo, Madrid, Barcelona, Castellon, Seville, Valencia
2018-06-19
Active, closed
Centre Hospitalier Universitaire de Besancon
Not applicable
989
Barcelona, Castellon, Donostia / San Sebastian, Girona, Madrid, Vigo
2018-05-03
Recruiting
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
NCT03460977Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL)
DrugsMevrometostat·Xtandi·Itraconazole·Enzalutamide
Pfizer
Phase 1
453
L'Hospitalet de Llobregat, Castellon, Pozuelo de Alarcón, Barcelona, Madrid, Málaga, Valencia
2018-04-17
Recruiting
Prostate Cancer Clinical Trials Consortium
Observational
5,000
Barcelona, Málaga, Valencia, Badalona, Castellon, Madrid, Oviedo, Zaragoza
2017-07-21
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,503
Barakaldo, Barcelona, Castellon, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Málaga, Reus
2015-11-19
Active, closed
Alliance Foundation Trials, LLC.
Phase 3
5,796
A Coruña, Alicante, Badalona, Barcelona, Burgos, Castellon, Cáceres, Córdoba
2015-08
Active, closed
AstraZeneca
Phase 3
1,837
A Coruña, Ávila, Badajoz, Badalona, Barcelona, Castellon, Cáceres, Córdoba
2014-04-22
Recruiting
Jules Bordet Institute
Not applicable
1,000
A Coruña, Barcelona, Castellon, Cáceres, Lleida, Madrid, Seville, Valencia
2014-04
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,207
A Coruña, Badalona, Barcelona, Castellon, Girona, Guadalajara, Jerez de la Frontera, Las Palmas de Gran Canaria
2013-10-14
Active, closed
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
NCT01272037Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma, Multifocal Breast Carcinoma
DrugsTamoxifen Citrate·Tamoxifen·Exemestane·Anastrozole
National Cancer Institute (NCI)
Phase 3
5,018
A Coruña, Albacete, Barcelona, Castellon, Cáceres, Donostia / San Sebastian, Girona, Madrid
2011-02-28
Rows per page Showing 1–68 of 68
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 October 2026. https://priyalifescience.com/clinical-trials-spain/city/castellon

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,875 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 68 of those studies with a site in Castellon.

How many clinical trials are recruiting in Castellon?

34 of the 68 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 3 have not yet opened recruitment, 30 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Castellon), 68 studies
PhaseStudiesRecruitingShare
Phase 3301144.1%
Not applicable151122.1%
Observational9713.2%
Phase 2608.8%
Phase 2/3435.9%
Phase 4314.4%
Phase 1111.5%

Most active sponsors

Lead sponsors with the most studies (Castellon)
Lead sponsorStudiesRecruiting
AstraZeneca83
Universitat Jaume I86
Janssen Research & Development, LLC52
MedSIR31
Aragon Pharmaceuticals, Inc.20
Biogen20
BioNTech SE22
Fundación EPIC20
Institut d'Investigació Biomèdica de Bellvitge22
Regeneron Pharmaceuticals21
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.